GlaxoSmithKline says five late-stage trials meet main goal
(Reuters) - GlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.
GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.
(Reporting by Monika Shinghal in Bangalore)
- Tweet this
- Share this
- Digg this
- Qatar will not host 2022 World Cup, says FIFA's Zwanziger
- U.S. and Arab allies launch first strikes on militants in Syria |
- Israel says its troops kill Hamas men accused of slaying teens |
- Britain close to joining U.S.-led air strikes against Islamic State
- AstraZeneca, Shire dive as U.S. tax move punctures deal hopes